ONCOGENESIS.AIPre-trial hypothesis stress testingField Brief
Bispecifics and T-cell engagers feel powerful because their mechanism is so visually legible: bring immune cells to the target, trigger engagement, and watch activity appear. The field-level risk is that activation can look more mature than the underlying control architecture really is.
Field-level reading, not company-level attack
Use to pressure-test active program logic
Activation strength can outrun durability.
These programs generate confidence quickly because they often show immediate pharmacologic or immune-redirection signal. That makes the field feel unusually tangible. But a field can be tangible at the activation layer and still remain fragile at the durability layer once exhaustion, toxicity, target escape, and sequence pressure become real.
Immune-redirection platforms often persuade early because the mechanism feels operational rather than abstract. The intervention seems to do exactly what it was designed to do: create proximity, induce engagement, and produce measurable pressure. That can make the field feel more settled than other modalities at the same stage.
But immediate mechanism-readout strength is not yet proof that the treatment architecture remains control-preserving over time. The field becomes dangerous when activation readouts start standing in for durability evidence.
The hidden instability often appears after the first impressive layer. Tolerability can narrow the window, exhaustion can erode persistence, target escape can weaken continuity, and the sequence can become harder to sustain than the early signal suggested.
That is why the field-level stress test matters. The right question is not whether redirection works. It is whether redirected pressure remains governable long enough, cleanly enough, and broadly enough to justify durable-control confidence.
Does redirected activation remain durable once the system pushes back through exhaustion, escape, or tolerability limits?
Early activity can be overread as durable control before the sequence can prove it holds over time.
Use this field brief when immune-redirection programs look compelling on first pass and the real decision risk is whether the activation story is outrunning durability evidence.
Field Boundary
This page maps field-level fragility. It does not claim program-specific confidence from public evidence alone. If a live thesis sits inside this pattern, that is usually the point to move from field-level pattern recognition to program-specific stress testing.